Non-steroidal anti-inflammatory treatment in cancer cachexia: A systematic literature review
Open Access
- 1 October 2012
- journal article
- review article
- Published by Taylor & Francis in Acta Oncologica
- Vol. 52 (1), 6-17
- https://doi.org/10.3109/0284186x.2012.724536
Abstract
Background. There are no established treatments for cachexia. Recently it has been suggested that the evidence for non-steroidal anti-inflammatory (NSAID) treatment is sufficient to support its regular clinical use. Primary objective in this systematic review was to assess efficacy and safety of NSAID treatment in improving body weight and muscle mass in patients with cancer cachexia. Secondary objectives were to assess whether this treatment could improve other cachexia domains such as anorexia and food intake, catabolic drive and function. Material and methods. A systematic literature review of PubMed, EMBASE and Cochrane Central register of controlled trials database was carried out using both text words and MeSH/EMTREE terms. Results. Thirteen studies were included; all but two trials showed either improvement or stabilization in weight or lean body mass. Seven studies were without a comparator. Studies are generally small and a few are methodologically flawed, often due to multiple outcomes with excess risk of false positives. Conclusion. NSAIDs may improve weight in cancer patients with cachexia, and there is some evidence on effect on physical performance, self-reported quality of life and inflammatory parameters. Evidence is too frail to recommend NSAID for cachexia outside clinical trials. This is supported by the known side effects of NSAIDs, even though the reviewed literature report almost negligible toxicity.Keywords
This publication has 45 references indexed in Scilit:
- Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectumOncology Reports, 2012
- Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trialsThe Lancet, 2012
- Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trialsThe Lancet, 2012
- Non-steroidal anti-inflammatory drugs and cancer incidence by sex in the VITamins And Lifestyle (VITAL) cohortCancer Causes & Control, 2012
- A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT StudyBMC Cancer, 2011
- Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancerLung Cancer, 2011
- Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational StudiesPLoS Medicine, 2011
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- Comparing safety and efficacy of first‐line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancerCancer, 2009
- Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib TrialCancer Prevention Research, 2009